AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03187509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Outpatient Heart Failure Management
Description: Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
Study NCT03015493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization combined with traction
Description: Neural mobilization techniques combined with cervical traction for the cervical nerve roots
Study NCT03015493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traction
Description: Traction techniques for the cervical spine
Study NCT02886130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
Study NCT02886130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
Study NCT01944020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: use of CPAP each night for 2 months
Study NCT02422329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete questionnaires at baseline and after intervention.
Study NCT02422329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
Study NCT02422329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact Sheet
Description: Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
Study NCT03717363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational talk
Description: An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
Study NCT00525408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium w.
Description: Immunomodulator
Study NCT02835586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
Study NCT00560508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole Immediate Release
Description: titrated as individually needed (0.25 mg - 4.5 mg daily)
Study NCT00560508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Extended Release
Description: titration as individually needed (0.375 mg -4.5 mg daily)
Study NCT03963596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal injection to the regimen pro re nata.
Study NCT01354223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A contact lens
Description: Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
Study NCT01354223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ocufilcon B contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study NCT01400009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (Cholecalciferol )
Description: 10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
Study NCT00525408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Chemotherapeutic agent
Study NCT04721574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips EnergyUp Energy light HF3418/01
Description: high brightness LED light box
Study NCT04721574 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Philips EnergyUp Energy light HF3418/01 with filter
Description: high brightness LED light box with filters that reduced lamp output to less than 50 lux
Study NCT00145522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17ß-Estradiol/Dydrogesterone
Description: 1/5 mg/day for 12 cycles of 28 days
Study NCT01400009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard Placebo made of Lactose 100 mg
Study NCT01490034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metabolic effects of consuming energy dense beverages
Description: Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
Study NCT01490034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy dense solid food
Description: Effects of consuming energy dense solid food for two weeks on physiological responses
Study NCT00145522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tibolone
Description: 2,5 mg/day for 12 cycles of 28 days
Study NCT03690531 — intervention group
Intervention type: DEVICE
Intervention: Take-Pause virtual reality
Description: Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
Study NCT03690531 — intervention group
Intervention type: DEVICE
Intervention: Passive Distraction
Description: Standard or passive distraction technique, lasting 5 minutes.
Study NCT04276571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exergames with GRAIL virtual immersive reality environment
Description: The participants will perform exergames on GRAIL immersive virtual reality to improve balance (e.g. load shifts, exercises with adaptations to motor perturbations). GRAIL can provide proprioceptive and visual feedback to participants.
Study NCT01490034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy dilute beverages
Description: Effects of consuming energy dilute beverages for two weeks on physiological responses.
Study NCT01490034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy dilute solid food
Description: Effects of consuming energy dilute solid food for two weeks on physiological responses
Study NCT00577369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Levels
Description: The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
Study NCT03657836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sublimated mare milk supplement
Description: The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
Study NCT03657836 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard antibiotic therapy
Description: Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
Study NCT03657836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antibiotic therapy
Description: Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
Study NCT02385006 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Study NCT01534962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Oral administration, BID; for a maximum of 112 days.
Study NCT00412581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
Study NCT00412581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 600 mg/m\^2 intravenously on Day 1 of every study cycle.
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL
Study NCT04482725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
Study NCT04024059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management for adherence
Description: Incentives contingent on buprenorphine adherence
Study NCT04024059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management for abstinence
Description: Incentives contingent on opiate abstinence
Study NCT01497535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
Study NCT01534962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, BID; for a maximum of 112 days.
Study NCT05509036 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study NCT01760460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Study NCT01760460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for anacetrapib
Study NCT00651352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg nicotine lozenge
Description: marketed formulation
Study NCT00651352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg nicotine lozenge
Description: marketed formulation
Study NCT00651352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine prototype
Description: 2 mg
Study NCT00651352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine prototype
Description: 4 mg
Study NCT00282984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 mg placebo twice daily by mouth for 12 weeks
Study NCT00282984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 1 mg twice daily by mouth for 12 weeks
Study NCT04802317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of the composition of the intestinal microbiota
Description: Identification of the composition of the intestinal microbiota
Study NCT05808114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friends program
Description: A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
Study NCT01497535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
Study NCT00614653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV Over 90 Minutes Every 2 Weeks
Study NCT00614653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg by mouth Once Daily on days with radiation.
Study NCT00614653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 400 mg/m\^2 PO Twice Daily on days with radiation.
Study NCT00614653 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
Study NCT02729077 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximetry
Description: Use of pulse oximetry device for 48 hours after surgery.
Study NCT00187629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary phosphorus
Description: varying amts dietary phosphorus
Study NCT00187629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary phosphorus
Description: varying amts dietary phosphorus
Study NCT01943422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Interferon alfa-2b
Description: •Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
Study NCT01943422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene.
Study NCT03520439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
Study NCT03954314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
Study NCT00999765 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: eight-week (two hours a week) group therapy (8-12 patients per group)
Study NCT00679536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
Study NCT00679536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m\^2/day.
Study NCT00679536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
Study NCT00679536 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
Study NCT04304365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up clinic visit
Description: Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.
Study NCT04304365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message
Description: Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.
Study NCT04304365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sensitivity Pregnancy Test (LSPT)
Description: Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
Study NCT03795714 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IVUS or OCT and Invasive physiologic indices
Description: IVUS or OCT measurement in order to evaluate the lesion morphology and stent optimization, and invasive physiologic measurement in order to functional significance of epicardial stenosis
Study NCT01776463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-360
Study NCT01776463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04476966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bladogra
Description: 1 tablet contains 25 mg Mirabegron
Study NCT04476966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrbetriq (first dosing)
Description: 1 tablet contains 25 mg Mirabegron
Study NCT04476966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrbetriq (second dosing)
Description: 1 tablet contains 25 mg Mirabegron
Study NCT01006941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Description: 2500 ova per dose, orally, every second week, during 12 weeks
Study NCT03735134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Loading Dose
Description: Two milligrams of colchicine will be administrated in addition to the standard of care treatment
Study NCT03735134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment prior to elective PCI
Description: All medications normally given to patients prior to elective PCI
Study NCT00618930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moviprep®
Description: use of Moviprep®
Study NCT00618930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet
Description: Use of Fleet
Study NCT01043120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Barusiban
Description: IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
Study NCT01043120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
Study NCT03373136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polypectomy
Description: Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
Study NCT03373136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypectomy
Description: Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
Study NCT02128217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
Study NCT02128217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
Study NCT02128217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Description: Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
Study NCT02098096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Work
Description: Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:~1. Familiarization~2. Acclimatization~3. Progression~Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.~All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer.
Study NCT02098096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
Study NCT00971841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT03192241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pump
Description: Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
Study NCT03192241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Book
Description: Active control intervention is providing mother's with a children's book and information about reading to baby.
Study NCT00706381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sincalide
Study NCT00706381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Study NCT00706381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Meal
Description: 600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate
Study NCT00706381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carb meal
Description: 600 calorie meal containing 100% carbohydrate
Study NCT03786042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette ad exposure
Description: Participants view a series of e-cigarette TV commercials
Study NCT03786042 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non e-cigarette TV commercials
Description: Participants view a series of non e-cigarette TV commercials